Vertebral Technologies (VTI) was granted a U.S. patent addressing modular, in vivo assembly technology and its motion preservation InterCushion® pipeline product. VTI now has 25+ patents and patent pending assets in its global intellectual property portfolio.
In clinical trials in Canada, InterCushion lumbar spine motion preservation product has demonstrated success in reducing pain, preserving the disc and halting modic changes. Numerous patients are at or near 5 years post-implantation, with continued clinically successful outcomes.
Earlier this month, the company reported successful outcomes from the first lumbar fusion procedure in Mexico using its InterFuse® laterally-expandable device.
Vertebral Technologies (VTI) was granted a U.S. patent addressing modular, in vivo assembly technology and its motion preservation InterCushion® pipeline product. VTI now has 25+ patents and patent pending assets in its global intellectual property portfolio.
In clinical trials in Canada, InterCushion lumbar spine motion preservation...
Vertebral Technologies (VTI) was granted a U.S. patent addressing modular, in vivo assembly technology and its motion preservation InterCushion® pipeline product. VTI now has 25+ patents and patent pending assets in its global intellectual property portfolio.
In clinical trials in Canada, InterCushion lumbar spine motion preservation product has demonstrated success in reducing pain, preserving the disc and halting modic changes. Numerous patients are at or near 5 years post-implantation, with continued clinically successful outcomes.
Earlier this month, the company reported successful outcomes from the first lumbar fusion procedure in Mexico using its InterFuse® laterally-expandable device.
Copy to clipboard 
